{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:03:58Z","timestamp":1781251438325,"version":"3.54.1"},"reference-count":66,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>Acute myeloid leukemia (AML) is the most common acute leukemia in adults in the United States and has seen the approval of several novel agents over the past decade. Similar to treatments for other hematologic and solid malignancies, these novel agents are costly. In the setting of finite financial resources in the healthcare system, the concept of cost-effectiveness analyses has been developed to compare the estimated costs and associated benefits expected with different interventions (eg, drugs, diagnostic tests, procedures). Although drug approvals in the United States are not based on budgetary considerations, cost-effectiveness analyses can inform health policy decisions, resource allocation, and societal debates. However, such analyses are only capturing parts of the costs and benefits to the healthcare system, payers, and consumers, and are based on modeling assumptions with inherent limitations. In addition, cost-effectiveness analyses for several of the novel agents approved for treatment of AML are limited and have reported conflicting results. This review uses cost-effectiveness analyses of azacitidine\/venetoclax and liposomal cytarabine\/daunorubicin as examples to review considerations and best practices when conducting and interpreting such studies. To ensure adequate interpretability of cost-effectiveness studies, transparency in the model inputs\/assumptions, data sources, and funding is of great importance, as evidenced by the discrepant conclusions across studies. Furthermore, the perspective and the healthcare system from which a cost-effectiveness analysis is conducted are important to consider because practice patterns and drug prices between countries can be variable. However, with advances in health economic modeling techniques, adherence to best practices, and increasing public interest in these types of studies, cost-effectiveness analyses can become an important tool to inform various stakeholders in the healthcare system to allocate limited resources most efficiently.<\/jats:p>","DOI":"10.6004\/jnccn.2023.70012","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T14:55:20Z","timestamp":1681138520000},"page":"522-528","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?"],"prefix":"10.6004","volume":"21","author":[{"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML)","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML). Accessed January 17, 2023. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"B2","series-title":"Blood Cancer J","first-page":"41","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian H","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C,  Acute myeloid leukemia: current progress and future directions. Blood Cancer J 2021;11:41."},{"key":"B3","series-title":"Lancet Oncol","first-page":"664","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","volume":"21","author":"Vokinger KN","year":"2020","unstructured":"Vokinger KN, Hwang TJ, Grischott T,  Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 2020;21:664\u2013670."},{"key":"B4","series-title":"J Oncol Pract","first-page":"357","article-title":"Payment for oncolytics in the United States: a history of buy and bill and proposals for reform","volume":"10","author":"Polite BN","year":"2014","unstructured":"Polite BN, Ward JC, Cox JV,  Payment for oncolytics in the United States: a history of buy and bill and proposals for reform. J Oncol Pract 2014;10:357\u2013362."},{"key":"B5","article-title":"Patient survival, health care utilization, and costs in Medicare patients with acute myeloid leukemia compared with matched controls","author":"Meyers J","unstructured":"Meyers J, Yu Y, Davis KL. Patient survival, health care utilization, and costs in Medicare patients with acute myeloid leukemia compared with matched controls. Presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; June 1, 2012; Washington, DC."},{"key":"B6","series-title":"Expert Rev Hematol","first-page":"641","article-title":"Healthcare expenses for treatment of acute myeloid leukemia","volume":"12","author":"Bewersdorf JP","year":"2019","unstructured":"Bewersdorf JP, Shallis RM, Wang R,  Healthcare expenses for treatment of acute myeloid leukemia. Expert Rev Hematol 2019;12:641\u2013650."},{"key":"B7","series-title":"JAMA","first-page":"1093","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders GD","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A,  Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093\u20131103."},{"key":"B8","series-title":"N Engl J Med","first-page":"796","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann PJ","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796\u2013797."},{"key":"B9","series-title":"Value Health","first-page":"385","article-title":"The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review","volume":"25","author":"Kazibwe J","year":"2022","unstructured":"Kazibwe J, Gheorghe A, Wilson D,  The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review. Value Health 2022;25:385\u2013389."},{"key":"B10","series-title":"Bull World Health Organ","first-page":"925","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram MY","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K,  Cost-effectiveness thresholds: pros and cons. Bull World Health Organ 2016;94:925\u2013930."},{"key":"B11","series-title":"Health Technol Assess","first-page":"1","article-title":"Methods for the estimation of the National Institute for Health and Care Excellence cost effectiveness threshold","volume":"19","author":"Claxton K","year":"2015","unstructured":"Claxton K, Martin S, Soares M,  Methods for the estimation of the National Institute for Health and Care Excellence cost effectiveness threshold. Health Technol Assess 2015;19:1\u2013503; v\u2013vi."},{"key":"B12","series-title":"J Clin Oncol","first-page":"332","article-title":"Systematic review of the cost effectiveness of breast cancer prevention, screening, and treatment interventions","volume":"38","author":"Jayasekera J","year":"2020","unstructured":"Jayasekera J, Mandelblatt JS. Systematic review of the cost effectiveness of breast cancer prevention, screening, and treatment interventions. J Clin Oncol 2020;38:332\u2013350."},{"key":"B13","series-title":"Expert Rev Hematol","first-page":"79","article-title":"Economic burden associated with acute myeloid leukemia treatment","volume":"9","author":"Zeidan AM","year":"2016","unstructured":"Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT,  Economic burden associated with acute myeloid leukemia treatment. Expert Rev Hematol 2016;9:79\u201389."},{"key":"B14","series-title":"Clin Transplant","first-page":"124","article-title":"Total costs and clinical outcome of hematopoietic stem cell transplantation in adults with leukemia: comparison between reduced-intensity and myeloablative conditioning","volume":"29","author":"Suh KJ","year":"2015","unstructured":"Suh KJ, Kim I, Lim J,  Total costs and clinical outcome of hematopoietic stem cell transplantation in adults with leukemia: comparison between reduced-intensity and myeloablative conditioning. Clin Transplant 2015;29:124\u2013133."},{"key":"B15","series-title":"Biol Blood Marrow Transplant","first-page":"1620","article-title":"Costs and cost-effectiveness of hematopoietic cell transplantation","volume":"18","author":"Preussler JM","year":"2012","unstructured":"Preussler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:1620\u20131628."},{"key":"B16","series-title":"Int J Technol Assess Health Care","first-page":"683","article-title":"The economic costs of acute myeloid leukemia in Sweden","volume":"10","author":"Tennvall GR","year":"1994","unstructured":"Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care 1994;10:683\u2013694."},{"key":"B17","article-title":"Burden of illness (BOI) of FLT3- mutated acute myeloid leukemia (AML)","author":"Sotak ML","unstructured":"Sotak ML, Marin M, Coombs J,  Burden of illness (BOI) of FLT3- mutated acute myeloid leukemia (AML). Presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; June 1, 2012; Washington, DC."},{"key":"B18","series-title":"J Med Econ","first-page":"556","article-title":"Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations","volume":"21","author":"Stein EM","year":"2018","unstructured":"Stein EM, Bonifacio G, Latremouille-Viau D,  Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. J Med Econ 2018;21:556\u2013563."},{"key":"B19","series-title":"Cancer Treat Rev","first-page":"224","article-title":"Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia","volume":"69","author":"Bosshard R","year":"2018","unstructured":"Bosshard R, O\u2019Reilly K, Ralston S,  Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia. Cancer Treat Rev 2018;69:224\u2013232."},{"key":"B20","series-title":"J Med Econ","first-page":"1119","article-title":"Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia","volume":"21","author":"Hagiwara M","year":"2018","unstructured":"Hagiwara M, Sharma A, Chung KC,  Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia. J Med Econ 2018;21:1119\u20131130."},{"key":"B21","series-title":"Cancers (Basel)","first-page":"1921","article-title":"Healthcare resource utilization among patients between 60-75 years with secondary acute myeloid leukemia receiving intensive chemotherapy induction: a Spanish retrospective observational study","volume":"14","author":"Solana-Altabella A","year":"2022","unstructured":"Solana-Altabella A, Meg\u00edas-Vericat JE, Ballesta-L\u00f3pez O,  Healthcare resource utilization among patients between 60-75 years with secondary acute myeloid leukemia receiving intensive chemotherapy induction: a Spanish retrospective observational study. Cancers (Basel) 2022;14:1921."},{"key":"B22","series-title":"EJHaem","first-page":"385","article-title":"Socioeconomic cost of AML in Sweden\u2014a population-based study using multiple nation-wide registers","volume":"2","author":"Hernlund E","year":"2021","unstructured":"Hernlund E, Redig J, Paulsson B,  Socioeconomic cost of AML in Sweden\u2014a population-based study using multiple nation-wide registers. EJHaem 2021;2:385\u2013393."},{"key":"B23","series-title":"Curr Opin Hematol","first-page":"65","article-title":"Outpatient induction and consolidation care strategies in acute myeloid leukemia","volume":"26","author":"Halpern AB","year":"2019","unstructured":"Halpern AB, Walter RB, Estey EH. Outpatient induction and consolidation care strategies in acute myeloid leukemia. Curr Opin Hematol 2019;26:65\u201370."},{"key":"B24","series-title":"J Med Econ","first-page":"567","article-title":"Health state utilities associated with treatment options for acute myeloid leukemia (AML)","volume":"22","author":"Matza LS","year":"2019","unstructured":"Matza LS, Deger KA, Howell TA,  Health state utilities associated with treatment options for acute myeloid leukemia (AML). J Med Econ 2019;22:567\u2013576."},{"key":"B25","series-title":"JAMA Oncol","first-page":"1120","article-title":"Resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia or myelodysplastic syndrome: a nonrandomized clinical comparative analysis","volume":"1","author":"Vaughn JE","year":"2015","unstructured":"Vaughn JE, Othus M, Powell MA,  Resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia or myelodysplastic syndrome: a nonrandomized clinical comparative analysis. JAMA Oncol 2015;1:1120\u20131127."},{"key":"B26","series-title":"Blood","first-page":"1766","article-title":"Cost-effectiveness of liposomal cytarabine\/daunorubicin in patients with newly diagnosed acute myeloid leukemia","volume":"139","author":"Bewersdorf JP","year":"2022","unstructured":"Bewersdorf JP, Patel KK, Goshua G,  Cost-effectiveness of liposomal cytarabine\/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood 2022;139:1766\u20131770."},{"key":"B27","series-title":"Biol Blood Marrow Transplant","first-page":"1788","article-title":"Real-world economic burden associated with transplantation-related complications","volume":"23","author":"Perales MA","year":"2017","unstructured":"Perales MA, Bonafede M, Cai Q,  Real-world economic burden associated with transplantation-related complications. Biol Blood Marrow Transplant 2017;23:1788\u20131794."},{"key":"B28","series-title":"Eur J Haematol","first-page":"58","article-title":"Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: a multicenter international study","volume":"109","author":"Ito T","year":"2022","unstructured":"Ito T, Sanford D, Tomuleasa C,  Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: a multicenter international study. Eur J Haematol 2022;109:58\u201368."},{"key":"B29","series-title":"JAMA Oncol","first-page":"374","article-title":"Association of risk factors, mortality, and care costs of adults with acute myeloid leukemia with admission to the intensive care unit","volume":"3","author":"Halpern AB","year":"2017","unstructured":"Halpern AB, Culakova E, Walter RB,  Association of risk factors, mortality, and care costs of adults with acute myeloid leukemia with admission to the intensive care unit. JAMA Oncol 2017;3:374\u2013381."},{"key":"B30","series-title":"Blood","first-page":"722","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein EM","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA,  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130:722\u2013731."},{"key":"B31","series-title":"N Engl J Med","first-page":"617","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V,  Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617\u2013629."},{"key":"B32","series-title":"N Engl J Med","first-page":"2386","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo CD","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S,  Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378:2386\u20132398."},{"key":"B33","series-title":"Blood","first-page":"2137","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei AH","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V,  Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 2020;135:2137\u20132145."},{"key":"B34","series-title":"N Engl J Med","first-page":"1728","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl AE","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE,  Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019;381:1728\u20131740."},{"key":"B35","series-title":"N Engl J Med","first-page":"454","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone RM","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL,  Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377:454\u2013464."},{"key":"B36","series-title":"Lancet Haematol","first-page":"e481","article-title":"CPX-351 versus 7 + 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet JE","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF,  CPX-351 versus 7 + 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2021;8:e481\u2013491."},{"key":"B37","series-title":"N Engl J Med","first-page":"2526","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei AH","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C,  Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 2020;383:2526\u20132537."},{"key":"B38","series-title":"Leukemia","first-page":"379","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes JE","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A,  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 2019;33:379\u2013389."},{"key":"B39","series-title":"Lancet Oncol","first-page":"986","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills RK","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR,  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986\u2013996."},{"key":"B40","series-title":"Blood","first-page":"2024","article-title":"Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma","volume":"140","author":"Kambhampati S","year":"2022","unstructured":"Kambhampati S, Saumoy M, Schneider Y,  Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood 2022;140:2024\u20132036."},{"key":"B41","series-title":"JAMA Netw Open","first-page":"e2135123","article-title":"Characteristics of cost-effectiveness studies for oncology drugs approved in the United States from 2015\u20132020","volume":"4","author":"Haslam A","year":"2021","unstructured":"Haslam A, Lythgoe MP, Greenstreet Akman E,  Characteristics of cost-effectiveness studies for oncology drugs approved in the United States from 2015\u20132020. JAMA Netw Open 2021;4:e2135123."},{"key":"B42","series-title":"BMJ","first-page":"e069573","article-title":"Industry sponsorship bias in cost effectiveness analysis: registry based analysis","volume":"377","author":"Xie F","year":"2022","unstructured":"Xie F, Zhou T. Industry sponsorship bias in cost effectiveness analysis: registry based analysis. BMJ 2022;377:e069573."},{"key":"B43","series-title":"J Clin Oncol","first-page":"2684","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet JE","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE,  CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684\u20132692."},{"key":"B44","series-title":"J Med Econ","first-page":"714","article-title":"Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk\/ secondary acute myeloid leukemia","volume":"23","author":"Villa KF","year":"2020","unstructured":"Villa KF, Ryan RJ, Chiarella M,  Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk\/ secondary acute myeloid leukemia. J Med Econ 2020;23:714\u2013720."},{"key":"B45","series-title":"Clinicoecon Outcomes Res","first-page":"21","article-title":"Comparison of hospital length of stay and supportive care utilization between patients treated with CPX-351 and 7 + 3 for therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes","volume":"14","author":"Price K","year":"2022","unstructured":"Price K, Cao Z, Lipkin C,  Comparison of hospital length of stay and supportive care utilization between patients treated with CPX-351 and 7 + 3 for therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Clinicoecon Outcomes Res 2022;14:21\u201334."},{"key":"B46","series-title":"Blood","article-title":"Cost-effectiveness of CPX-351 versus 7 + 3 regimen in the treatment of treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC)","volume":"130","author":"Kansal A","year":"2017","unstructured":"Kansal A, Du M, Herrera-Restrepo O,  Cost-effectiveness of CPX-351 versus 7 + 3 regimen in the treatment of treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC). Blood 2017;130(Suppl 1):Abstract 4674."},{"key":"B47","series-title":"Br J Cancer","first-page":"1405","article-title":"Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations","volume":"89","author":"Hartmann M","year":"2003","unstructured":"Hartmann M, Knoth H, Schulz D,  Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer 2003;89:1405\u20131408."},{"key":"B48","series-title":"BMJ Open","first-page":"e012648","article-title":"Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding","volume":"7","author":"Al-Badriyeh D","year":"2017","unstructured":"Al-Badriyeh D, Alameri M, Al-Okka R. Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding. BMJ Open 2017;7:e012648."},{"key":"B49","series-title":"JAMA Oncol","first-page":"274","article-title":"Associations between industry sponsorship and results of cost-effectiveness analyses of drugs used in breast cancer treatment","volume":"2","author":"Lane JD","year":"2016","unstructured":"Lane JD, Friedberg MW, Bennett CL. Associations between industry sponsorship and results of cost-effectiveness analyses of drugs used in breast cancer treatment. JAMA Oncol 2016;2:274\u2013276."},{"key":"B50","series-title":"Blood Adv","first-page":"994","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel KK","year":"2021","unstructured":"Patel KK, Zeidan AM, Shallis RM,  Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv 2021;5:994\u20131002."},{"key":"B51","series-title":"PharmacoEconomics","first-page":"777","article-title":"Cost-effectiveness analysis of venetoclax in combination with azacitidine versus azacitidine monotherapy in patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: from a US third party payer perspective","volume":"40","author":"Pratz KW","year":"2022","unstructured":"Pratz KW, Chai X, Xie J,  Cost-effectiveness analysis of venetoclax in combination with azacitidine versus azacitidine monotherapy in patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: from a US third party payer perspective. PharmacoEconomics 2022;40:777\u2013790."},{"key":"B52","series-title":"Haematologica","first-page":"2659","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf JP","year":"2020","unstructured":"Bewersdorf JP, Giri S, Wang R,  Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica 2020;105:2659\u20132663."},{"key":"B53","series-title":"Cancer","first-page":"3541","article-title":"Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy","volume":"127","author":"Venugopal S","year":"2021","unstructured":"Venugopal S, Shoukier M, Konopleva M,  Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 2021;127:3541\u20133551."},{"key":"B54","series-title":"Blood Adv","first-page":"3997","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews AH","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM,  Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 2022;6:3997\u20134005."},{"key":"B55","series-title":"Transplant Cell Ther","first-page":"694.e1","article-title":"Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy","volume":"28","author":"Winters AC","year":"2022","unstructured":"Winters AC, Bosma G, Abbott D,  Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy. Transplant Cell Ther 2022;28:694.e1\u20139."},{"key":"B56","series-title":"Leuk Lymphoma","first-page":"3394","article-title":"Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant","volume":"62","author":"Bewersdorf JP","year":"2021","unstructured":"Bewersdorf JP, Derkach A, Gowda L,  Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leuk Lymphoma 2021;62:3394\u20133401."},{"key":"B57","series-title":"Blood Adv","first-page":"4686","article-title":"Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia","volume":"5","author":"Bewersdorf JP","year":"2021","unstructured":"Bewersdorf JP, Patel KK, Huntington SF,  Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. Blood Adv 2021;5:4686\u20134690."},{"key":"B58","article-title":"Inflation Reduction Act of 2022. Pub L No. 117\u2013169","unstructured":"Inflation Reduction Act of 2022. Pub L No. 117\u2013169. Accessed March 28, 2023. Available at: https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\/text"},{"key":"B59","series-title":"N Engl J Med","first-page":"1437","article-title":"Impending relief for Medicare beneficiaries \u2014 the Inflation Reduction Act","volume":"387","author":"Dusetzina SB","year":"2022","unstructured":"Dusetzina SB, Huskamp HA. Impending relief for Medicare beneficiaries \u2014 the Inflation Reduction Act. N Engl J Med 2022;387:1437\u20131439."},{"key":"B60","series-title":"Leuk Res","first-page":"106942","article-title":"Efficacy of FLT3 and IDH1\/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax","volume":"122","author":"Bewersdorf JP","year":"2022","unstructured":"Bewersdorf JP, Shallis RM, Derkach A,  Efficacy of FLT3 and IDH1\/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leuk Res 2022;122:106942."},{"key":"B61","series-title":"Leuk Lymphoma","article-title":"Venetoclax-based salvage therapy in patients with relapsed\/refractory acute myeloid leukemia previously treated with FLT3 or IDH1\/2 inhibitors","author":"Bewersdorf JP","unstructured":"Bewersdorf JP, Shallis RM, Derkach A,  Venetoclax-based salvage therapy in patients with relapsed\/refractory acute myeloid leukemia previously treated with FLT3 or IDH1\/2 inhibitors Leuk Lymphoma. Published online October 26, 2022. doi:10.1080\/10428194.2022.2136952"},{"key":"B62","series-title":"Leuk Lymphoma","article-title":"Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia","author":"Bewersdorf JP","unstructured":"Bewersdorf JP, Patel KK, Goshua G,  Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia Leuk Lymphoma. Published online December 9, 2022. doi:10.1080\/10428194.2022.2140288"},{"key":"B63","series-title":"Clin Cancer Res","first-page":"2753","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea DA","year":"2022","unstructured":"Pollyea DA, DiNardo CD, Arellano ML,  Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations. Clin Cancer Res 2022;28:2753\u20132761."},{"key":"B64","series-title":"Blood Adv","first-page":"1552","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/ refractory AML","volume":"5","author":"Stahl M","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A,  Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/ refractory AML. Blood Adv 2021;5:1552\u20131564."},{"key":"B65","series-title":"J Clin Oncol","first-page":"1119","article-title":"Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma","volume":"39","author":"Patel KK","year":"2021","unstructured":"Patel KK, Giri S, Parker TL,  Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma. J Clin Oncol 2021;39:1119\u20131128."},{"key":"B66","series-title":"Blood","first-page":"1946","article-title":"Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia","volume":"136","author":"Patel KK","year":"2020","unstructured":"Patel KK, Isufi I, Kothari S,  Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020;136:1946\u20131955."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/5\/article-p522.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/5\/article-p522.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/5\/article-p522.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T19:51:16Z","timestamp":1683575476000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/5\/article-p522.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":66,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.70012","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}